PhD student Anja Ritter made a pitch presentation of her work on the TME gene engineering vector Ad825 at the annual CIMT meeting 2026.
May 11, 2026
Our research was represented by the PhD students Ahmed Calandigary and Anja Ritter at the annual CIMT meeting 2026 and presented two posters: ”Targeting soft-tissue sarcoma with tumor microenvironment gene engineering drives NK cell antitumoral responses and reduces factors that promote tumor progression” Calandigary et al, and ”Immunostimulatory gene therapy targeting CD40, 4-1BB, and PD-L1 reactivates T cell immunity" Ritter et al.
April 19, 2026
Angelica Loskog, CEO/CSO at Lokon, released our promising data combining LOAd703 with nab-paclitaxel, gemcitabine, and atezolizumab (anti-PD-L1) in pancreatic cancer during an oral presentation at the annual AACR meeting.
We have been informed that individuals are receiving fraudulent job interview invitations claiming to be from Lokon Pharma. Please be aware that Lokon Pharma is not conducting any recruitment or job interviews at this time. Any message, email, or phone call offering an interview or job opportunity with our company is not legitimate.
If you receive such communication, do not respond, do not provide any personal information, and do not send any money. These contacts are part of an ongoing scam.
For your safety, please report suspicious messages to your local authorities